Continuous release of endostatin from microencapsulated engineered cells for tumor therapy

Tatsuhiro Joki, Marcelle Machluf, Anthony Atala, Jianhong Zhu, Nicholas T. Seyfried, Ian F. Dunn, Toshiaki Abe, Rona S. Carroll, Peter McL Black

Research output: Contribution to journalArticle

322 Citations (Scopus)

Abstract

Research studies suggest that tumor-related angiogenesis contributes to the phenotype of malignant gliomas. We assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell line (U-87MG) xenografts. Baby hamster kidney (BHK) cells were stably transfected with a human endostatin (hES) expression vector and were encapsulated in alginate-poly L-lysine (PLL) microcapsules for long-term delivery of hES. The release of biologically active endostatin was confirmed using assays of bovine capillary endothelial (BCE) proliferation and of tube formation. Human endostatin released from the microcapsules brought about a 67.2% inhibition of BCE proliferation. Furthermore, secreted hES was able to inhibit tube formation in KDR/PAE cells (porcine aortic endothelial cells stably transfected with KDR, a tyrosine kinase) treated with conditioned U-87MG medium. A single local injection of encapsulated endostatin-secreting cells in a nude mouse model resulted in a 72.3% reduction in subcutaneous U87 xenografts' weight 21 days post treatment. This inhibition was achieved by only 150.8 ng/ml human endostatin secreted from 2 × 105 encapsulated cells. Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalNature Biotechnology
Volume19
Issue number1
DOIs
StatePublished - Jan 27 2001
Externally publishedYes

Fingerprint

Endostatins
Cell- and Tissue-Based Therapy
Tumors
Neoplasms
Alginate
Endothelial cells
Heterografts
Assays
Cells
Glioma
Capsules
Vascular Endothelial Growth Factor Receptor-2
Angiogenesis Inhibitors
Therapeutics
Glioblastoma
Nude Mice
Cricetinae
Protein-Tyrosine Kinases
Swine
Endothelial Cells

Keywords

  • Angiogenesis
  • Encapsulation
  • Endostatin
  • Glioma

ASJC Scopus subject areas

  • Microbiology

Cite this

Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., ... Black, P. M. (2001). Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nature Biotechnology, 19(1), 35-39. https://doi.org/10.1038/83481

Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. / Joki, Tatsuhiro; Machluf, Marcelle; Atala, Anthony; Zhu, Jianhong; Seyfried, Nicholas T.; Dunn, Ian F.; Abe, Toshiaki; Carroll, Rona S.; Black, Peter McL.

In: Nature Biotechnology, Vol. 19, No. 1, 27.01.2001, p. 35-39.

Research output: Contribution to journalArticle

Joki, T, Machluf, M, Atala, A, Zhu, J, Seyfried, NT, Dunn, IF, Abe, T, Carroll, RS & Black, PM 2001, 'Continuous release of endostatin from microencapsulated engineered cells for tumor therapy', Nature Biotechnology, vol. 19, no. 1, pp. 35-39. https://doi.org/10.1038/83481
Joki, Tatsuhiro ; Machluf, Marcelle ; Atala, Anthony ; Zhu, Jianhong ; Seyfried, Nicholas T. ; Dunn, Ian F. ; Abe, Toshiaki ; Carroll, Rona S. ; Black, Peter McL. / Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. In: Nature Biotechnology. 2001 ; Vol. 19, No. 1. pp. 35-39.
@article{764f9e8756ab4619827fa145b9ce51b1,
title = "Continuous release of endostatin from microencapsulated engineered cells for tumor therapy",
abstract = "Research studies suggest that tumor-related angiogenesis contributes to the phenotype of malignant gliomas. We assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell line (U-87MG) xenografts. Baby hamster kidney (BHK) cells were stably transfected with a human endostatin (hES) expression vector and were encapsulated in alginate-poly L-lysine (PLL) microcapsules for long-term delivery of hES. The release of biologically active endostatin was confirmed using assays of bovine capillary endothelial (BCE) proliferation and of tube formation. Human endostatin released from the microcapsules brought about a 67.2{\%} inhibition of BCE proliferation. Furthermore, secreted hES was able to inhibit tube formation in KDR/PAE cells (porcine aortic endothelial cells stably transfected with KDR, a tyrosine kinase) treated with conditioned U-87MG medium. A single local injection of encapsulated endostatin-secreting cells in a nude mouse model resulted in a 72.3{\%} reduction in subcutaneous U87 xenografts' weight 21 days post treatment. This inhibition was achieved by only 150.8 ng/ml human endostatin secreted from 2 × 105 encapsulated cells. Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types.",
keywords = "Angiogenesis, Encapsulation, Endostatin, Glioma",
author = "Tatsuhiro Joki and Marcelle Machluf and Anthony Atala and Jianhong Zhu and Seyfried, {Nicholas T.} and Dunn, {Ian F.} and Toshiaki Abe and Carroll, {Rona S.} and Black, {Peter McL}",
year = "2001",
month = "1",
day = "27",
doi = "10.1038/83481",
language = "English",
volume = "19",
pages = "35--39",
journal = "Nature Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Continuous release of endostatin from microencapsulated engineered cells for tumor therapy

AU - Joki, Tatsuhiro

AU - Machluf, Marcelle

AU - Atala, Anthony

AU - Zhu, Jianhong

AU - Seyfried, Nicholas T.

AU - Dunn, Ian F.

AU - Abe, Toshiaki

AU - Carroll, Rona S.

AU - Black, Peter McL

PY - 2001/1/27

Y1 - 2001/1/27

N2 - Research studies suggest that tumor-related angiogenesis contributes to the phenotype of malignant gliomas. We assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell line (U-87MG) xenografts. Baby hamster kidney (BHK) cells were stably transfected with a human endostatin (hES) expression vector and were encapsulated in alginate-poly L-lysine (PLL) microcapsules for long-term delivery of hES. The release of biologically active endostatin was confirmed using assays of bovine capillary endothelial (BCE) proliferation and of tube formation. Human endostatin released from the microcapsules brought about a 67.2% inhibition of BCE proliferation. Furthermore, secreted hES was able to inhibit tube formation in KDR/PAE cells (porcine aortic endothelial cells stably transfected with KDR, a tyrosine kinase) treated with conditioned U-87MG medium. A single local injection of encapsulated endostatin-secreting cells in a nude mouse model resulted in a 72.3% reduction in subcutaneous U87 xenografts' weight 21 days post treatment. This inhibition was achieved by only 150.8 ng/ml human endostatin secreted from 2 × 105 encapsulated cells. Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types.

AB - Research studies suggest that tumor-related angiogenesis contributes to the phenotype of malignant gliomas. We assessed the effect of local delivery of the angiogenesis inhibitor endostatin on human glioma cell line (U-87MG) xenografts. Baby hamster kidney (BHK) cells were stably transfected with a human endostatin (hES) expression vector and were encapsulated in alginate-poly L-lysine (PLL) microcapsules for long-term delivery of hES. The release of biologically active endostatin was confirmed using assays of bovine capillary endothelial (BCE) proliferation and of tube formation. Human endostatin released from the microcapsules brought about a 67.2% inhibition of BCE proliferation. Furthermore, secreted hES was able to inhibit tube formation in KDR/PAE cells (porcine aortic endothelial cells stably transfected with KDR, a tyrosine kinase) treated with conditioned U-87MG medium. A single local injection of encapsulated endostatin-secreting cells in a nude mouse model resulted in a 72.3% reduction in subcutaneous U87 xenografts' weight 21 days post treatment. This inhibition was achieved by only 150.8 ng/ml human endostatin secreted from 2 × 105 encapsulated cells. Encapsulated endostatin-secreting cells are effective for the treatment of human glioblastoma xenografts. Continuous local delivery of endostatin may offer an effective therapeutic approach to the treatment of a variety of tumor types.

KW - Angiogenesis

KW - Encapsulation

KW - Endostatin

KW - Glioma

UR - http://www.scopus.com/inward/record.url?scp=0035172407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035172407&partnerID=8YFLogxK

U2 - 10.1038/83481

DO - 10.1038/83481

M3 - Article

C2 - 11135549

AN - SCOPUS:0035172407

VL - 19

SP - 35

EP - 39

JO - Nature Biotechnology

JF - Nature Biotechnology

SN - 1087-0156

IS - 1

ER -